Medical marijuana: Clearing away the smoke

Open Neurology Journal

Volumn 6, Issue 1, 2012, Pages 18-25

  Grant, Igor ^a   Hampton Atkinson, J ^a,b   Gouaux, Ben ^a   Wilsey, Barth ^c  

^a University of California   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cannabis; Chronic pain; Pain

Indexed keywords

ANTICONVULSIVE AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; CANNABINOID; CANNABIS; CHOLINERGIC RECEPTOR BLOCKING AGENT; CODEINE; DIHYDROCODEINE; DRONABINOL; METOCLOPRAMIDE; NABILONE; NABIXIMOLS; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; PLACEBO; TETRAHYDROCANNABINOL; TIZANIDINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY; AREA UNDER THE CURVE; ARTICLE; ATAXIA; CANCER PAIN; CANNABIS SMOKING; CHEMOTHERAPY INDUCED EMESIS; CHRONIC PAIN; COMORBIDITY; CONSTIPATION; COUGHING; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; DYSPHORIA; EUPHORIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HUMAN; HYPOTENSION; IRRITABILITY; LOW DRUG DOSE; MEMORY DISORDER; MENTAL DISEASE; MUSCLE WEAKNESS; MYALGIA; NARCOTIC DEPENDENCE; NAUSEA; NEUROMUSCULAR DISEASE; NEUROPATHIC PAIN; OPTIMAL DRUG DOSE; ORTHOSTATIC HYPOTENSION; PAIN; PAIN ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOSIS; RESTLESSNESS; RISK BENEFIT ANALYSIS; RISK FACTOR; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; TACHYCARDIA; THROAT IRRITATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VISUAL DISORDER; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 84861858686     PISSN: None     EISSN: 1874205X     Source Type: Journal    
DOI: 10.2174/1874205X01206010018     Document Type: Article

References (62)

1. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323(7303):13-16.
2. Noyes R, Brunk SF, Avery DA, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975;18(1): 84-89.
3. MA. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 2005; (168): 657-690.
4. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007; 68(7): 515-521.
5. Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacol 2009; 34(3): 672-680.
6. Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008; 9(6): 506-521.
7. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94(2):149-158.
8. Wallace M, Schulteis G, Atkinson JH, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007;107(5):785-796.
9. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010;182(14): E694-E701.
10. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362(9395): 1517-1526.
11. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329(7460):253.
12. Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 2008; 336(7637):199-201.
13. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323(7303):16-21.
14. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 2006; 105(1-2):1-25.
15. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manag 1995;10(2): 89-97.
16. Beal JE, Olson R, Lefkowitz L, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manag 1997; 14(1):7-14.
17. Pertwee RG. Cannabinoids and multiple sclerosis. Mol Neurobiol 2007; 36(1): 45-59.
18. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003;17(1): 21-29.
19. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004; 10(4): 417-424.
20. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10(4): 434-441.
21. Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther 2007; 82(5): 572-578.
22. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65(6):812-819.
23. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 2007;133(1-3): 210-220.
24. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manag 2010; 39(2): 167-179.
25. Collin C, Davies P, Mutiboko IK, Ratcliffe S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007; 14(3): 290-296.
26. Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2010; 16(6): 707-714.
27. Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006; 12(5): 639-645.
28. Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008; 30(5): 974-985.
29. Jones RT, Benowitz NL, Herning RI. Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 1981; 21(8-9 Suppl):143S-152S.
30. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005; 76(12):1664-1669.
31. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following oral THC administration to humans. Psychopharmacology (Berl) 1999;141(4): 385-394.
32. Haney M, Ward AS, Comer SD. Foltin RW, Fischman MW. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (Berl) 1999;141(4): 395-404.
33. Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004; 161(11): 1967-1977.
34. Williamson EM. Drug interactions between herbal and prescription medicines. Drug Safety 2003; 26: 1075-1092.
35. Wills S. Drugs of Abuse. 2nd ed. London: Pharmaceutical Press 2005.
36. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370(9584): 319-328.
37. D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci 2009; 259(7): 413-431.
38. McGrath J, Welham J, Scott J, et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry 2010; 67(5): 440-447.
39. van Winkel R. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry 2011; 68(2): 148-157.
40. Miller LL, McFarland D, Cornett TL, Brightwell D. Marijuana and memory impairment: effect on free recall and recognition memory. Pharmacol Biochem Behav 1977; 7(2): 99-103.
41. Sewell RA, Poling J, Sofuoglu M. The effect of cannabis compared with alcohol on driving. Am J Addict 2009; 18(3):185-193.
42. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009;374(9698):1383-1391.
43. Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med 2007; 167(3): 221-228.
44. Hashibe M, Morgenstern H, Cui Y, et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomark Prev 2006;15(10):1829-1834.
45. Mehra R, Moore BA, Crothers K, Tetrault J, Fiellin DA. The association between marijuana smoking and lung cancer: a systematic review. Arch Intern Med 2006;166(13):1359-1367.
46. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation 2001; 103(23): 2805-2809.
47. Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc 2003; 9(5):679-689.
48. Brunton L, Chabner B, Knollman B, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill 2010.
49. Mehmedic Z, Chandra S, Slade D, et al. Potency trends of Delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 2010; 55(5): 1209-1217.
50. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10(2): 113-130.
51. Fine PG, Portenoy RK. A Clinical Guide to Opioid Analgesia. 2nd ed. New York: Vendome Group 2007.
52. Jamison RN, Clark JD. Opioid medication management: clinician beware! Anesthesiology 2010; 112(4):777-778.
53. Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised screener and opioid assessment for Patients with Pain (SOAPP-R). J Pain 2008; 9(4): 360-372.
54. Reisfield GM, Wasan AD, Jamison RN. The prevalence and significance of cannabis use in patients prescribed chronic opioid therapy: a review of the extant literature. Pain Med 2009; 10(8): 1434-1441.
55. MA. Drug and alcohol abuse: a clinical guide to diagnosis and treatment. 6th ed. New York: Springer 2006.
56. Jamison RN, Ross EL, Michna E, Chen LQ, Holcomb C, Wasan AD. Substance misuse treatment for high-risk chronic pain patients on opioid therapy: a randomized trial. Pain 2010;150(3):390-400.
57. Ho TW, Backonja M, Ma J, Leibensperger H, Froman S, Polydefkis M. Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies. Pain 2009;141(1-2):19-24.
58. Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, Gouaux B. A randomized, placebo-controlled trial of smoked cannabis for spasticity in multiple sclerosis. CMAJ (In press).
59. Drug Enforcement Agency. The DEA Position on Marijuana. January 2011; Available from: http://www.justice.gov/dea/mari-juana_position.pdf. [cited 2012 March 26]
60. Cohen PJ. Medical marijuana: the conflict between scientific evidence and political ideology. Part two of two. J Pain Palliat Care Pharmacother 2009; 23(2): 120-140.
61. Cohen PJ. Medical marijuana: the conflict between scientific evidence and political ideology. Part one of two. J Pain Palliat Care Pharmacother 2009; 23(1): 4-25.
62. Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 2012; 344:e536